Shares of Puma Biotechnology PBYI rose 0.32 in after-market trading after the company reported Q2 results.
Earnings per share increased 136.08% year over year to $0.35, which beat the estimate of ($0.30).
Revenue of $70,600,000 higher by 30.98% from the same period last year, which beat the estimate of $58,210,000.
Earnings guidance hasn't been issued by the company for now.
Puma Biotechnology hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Aug 06, 2020
Time: 04:30 PM
52-week high: $15.00
Company's 52-week low was at $5.50
Price action over last quarter: down 9.91%
Puma Biotechnology is a biotechnology company focused on developing novel therapeutics for the treatment of cancer. Puma licenses the commercial rights to its current drug candidates. The company expects to augment its product pipeline by acquiring, through license or otherwise, additional drug candidates for research and development and potential commercialization. In evaluating potential drug candidates, Puma employs disciplined decision criteria favoring drug candidates that have undergone at least some clinical study.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.